COVID VACCINE

 

The American biotech company Modena has announced that the experimental vaccine against Kovid-19 is 94.5 percent effective. The US pharmaceutical company Pfizer had earlier announced that the vaccine was 90 percent effective. Following this, Modena also announced optimism. Modena also released the results from a clinical trial attended by more than 30,000 people. Both vaccines are based on a new platform called Messenger RNA. It is produced faster than conventional vaccines and makes human cells vaccine factories. Modena's vaccine contains genetic material called messenger RNA or MRNA, which is made in a lab. MRNA is basically a genetic code. It instructs cells on how to form protein. MRNA tells the body's own cellular systems to make proteins similar to viral proteins, thereby boosting the immune system. Modena CEO Stephen Bansal said the vaccine could help prevent Kovid-19 disease in a positive interim analysis of the third phase study. The company plans to submit applications for immediate approval in the U.S. and around the world within weeks. It is known that about 20 million doses will be ready for distribution in the US by the end of the year. The modena vaccine, developed in collaboration with the U.S. National Institutes of Health, is given in two doses over 28 days. Of the 95, 90 were in the trial 's placebo group and five were MRNA-1273 recipients. There were 11 people in critical condition, all in the placebo group. The vaccine worked well and most of the side effects were observed to be mild. Three percent of people were found to have severe injection site pain after the first dose. Severe side effects after the second dose were found in 10 percent of patients, nine percent with pain, five percent with joint pain, headache, four percent with other pain, and 2 percent with redness at the injection site. A company spokesman said the incidents were short-lived. The company added that the vaccine can be stored for up to six months at standard freezer temperatures of -20C (-4FF). However, Pfizer's vaccine needs to be stored in a cool place. This can be a major challenge for distribution, especially in developed countries. At the same time, it is not yet clear how much protection Modena and Pfizer vaccines will provide or how long they will work for the most vulnerable elderly from Kovid-19.